Based on the key indicators related to Aptevo Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aptevo Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Aptevo Therapeutics' Net Receivables is very stable compared to the past year. As of the 22nd of March 2025, Other Current Assets is likely to grow to about 2.9 M, while Total Assets are likely to drop about 14.8 M. Key indicators impacting Aptevo Therapeutics' financial strength include:
Investors should never underestimate Aptevo Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aptevo Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Aptevo Therapeutics.
Net Income
(25.34 Million)
Aptevo
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
Sale Purchase Of Stock
Change To Inventory
Investments
Change In Cash
Net Borrowings
Total Cashflows From Investing Activities
Change To Operating Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Begin Period Cash Flow
Change Receivables
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Common Stock Shares Outstanding
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Non Currrent Assets Other
Other Assets
Short Long Term Debt Total
Long Term Debt
Common Stock Total Equity
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Short Long Term Debt
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Discontinued Operations
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Non Operating Income Net Other
Extraordinary Items
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Aptevo Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aptevo Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Aptevo Therapeutics' assets may result in an increase in income on the income statement.
Aptevo Therapeutics competes with Kronos Bio, Cyclerion Therapeutics, Larimar Therapeutics, Addex Therapeutics, and Achilles Therapeutics. Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Aptevo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 54 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Aptevo Therapeutics's current stock value. Our valuation model uses many indicators to compare Aptevo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aptevo Therapeutics competition to find correlations between indicators driving Aptevo Therapeutics's intrinsic value. More Info.
Aptevo Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Aptevo Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aptevo Therapeutics' earnings, one of the primary drivers of an investment's value.
Aptevo Therapeutics Systematic Risk
Aptevo Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aptevo Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Aptevo Therapeutics correlated with the market. If Beta is less than 0 Aptevo Therapeutics generally moves in the opposite direction as compared to the market. If Aptevo Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aptevo Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aptevo Therapeutics is generally in the same direction as the market. If Beta > 1 Aptevo Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aptevo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aptevo Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aptevo Therapeutics growth as a starting point in their analysis.
Aptevo Therapeutics March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aptevo Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aptevo Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aptevo Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Aptevo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aptevo Therapeutics's daily price indicators and compare them against related drivers.
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(87.38)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.76)
Return On Equity
(2.84)
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.